Royalty Pharma plc has released a groundbreaking report conducted by Deloitte, titled "Role of Royalties in Funding Biopharma Innovation," which provides an in-depth analysis of the biopharma royalty market. The study, a first of its kind, gathers insights from over 110 biopharma executives, revealing the strategic importance of royalties in the industry's evolving capital landscape. Key findings highlight the non-dilutive nature of royalties, their flexibility, and positive investor perception, making them an attractive funding option for biopharma companies. The report suggests that royalties are increasingly recognized as vital to supporting innovation and scientific breakthroughs, with 87% of surveyed executives considering them in capital raising plans for the next three years. This marks a shift towards a diversified funding model in biopharma, emphasizing the significant role royalties play in providing flexible, large-scale capital. The full report is available for download on Deloitte's and Royalty Pharma's websites.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526512-en) on September 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.